Celano Michael
Known title: DirectorCIK: 0001377582
Celano Michael's purchase track record
How the stock did after each of Celano Michael's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since August 12, 2022
Stock higher 6 months later
67%
3 months: 100%
Median 6-month return
+9.2%
3 months: +16.0%
Beat the S&P 500
67%
median +13.6% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/17/2023 | LRMR | $19K | +8.7% | -20.6% | +8.3% |
| 9/16/2022 | LRMR | $100K | +40.0% | +68.1% | +1.1% |
| 8/12/2022 | OSUR | $54K | +16.0% | +9.2% | -4.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LRMR | ▲ Buy | Grant | 37,604 | $0 | 1/26/2026 | View on chart |
| LRMR | ▲ Buy | Grant | 34,185 | $0 | 1/22/2025 | View on chart |
| LRMR | ▲ Buy | Grant | 31,250 | $0 | 1/17/2024 | View on chart |
| LRMR | ▲ Buy | Open Market | 5,000 | $19K | 5/17/2023 | View on chart |
| LRMR | ▲ Buy | Grant | 76,000 | $0 | 1/31/2023 | View on chart |
| LRMR | ▲ Buy | Open Market | 31,746 | $100K | 9/16/2022 | View on chart |
| OSUR | ▲ Buy | Open Market | 12,000 | $54K | 8/12/2022 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 3,399 | $18K | 5/16/2022 | View on chart |
| OSUR | ▲ Buy | Grant | 24,762 | $130K | 5/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Larimar Therapeutics Names John Harlow as President and COO
Larimar Therapeutics has appointed John Harlow as its new President and Chief Operating Officer, effective September 29. This leadership change is intended to strengthen the company's executive team. The stock is currently trading near its 52-week low, which provides context for this operational update.
Larimar Therapeutics Names John Harlow as President and COO. Larimar Therapeutics has appointed John Harlow as its new President and Chief Operating Officer, effective September 29. This leadership change is intended to strengthen the company's executive team. The stock is currently trading near its 52-week low, which provides context for this operational update.